IP Library › Granted Patent US 12,312,382
Granted Patent B2
US 12,312,382 · App. 18/455,151 · Granted May 27, 2025

Recombinant adenoviruses and uses thereof

Inventors: Dan H. Barouch (Newton, MA); Peter Abbink (Winthrop, MA); Mark Justin Iampietro (Boston, MA); Menzo J. E. Havenga (Boston, MA)
Assignee: Beth Israel Deaconess Medical Center, Inc.
C07K14/075A61K31/7088A61K35/761A61K39/0011A61K39/235C07K14/5425C12N15/861
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,312,382
App. No.
18/455,151
Granted
May 27, 2025
Kind
B2
Abstract

Featured are recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are simian (rhesus) adenoviruses having a low seroprevalence and high immunogenicity (when expressing, e.g., an antigenic polypeptide) relative to other adenoviruses and vectors thereof. Also featured are methods for producing the adenoviruses and methods of treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).

Claims (23)

1. A recombinant adenovirus comprising a nucleotide sequence encoding a hexon protein, wherein the nucleotide sequence encoding the hexon protein has at least 93% sequence identity over the entire sequence of any one of SEQ ID NOs: 55, 58, 59, 61, 62, 64, 65, and 67, and wherein the recombinant adenovirus further comprises a deletion in or of the E1, E2, and/or E3 region.

2. The recombinant adenovirus of claim 1 , wherein the nucleotide sequence encoding the hexon protein has at least 94% sequence identity over the entire sequence of any one of SEQ ID NOs: 55, 58, 59, 61, 62, 64, 65, and 67.

3. The recombinant adenovirus of claim 1 , wherein the hexon protein comprises an amino acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 159, 162, 163, 165, 166, 168, 169, and 171.

4. The recombinant adenovirus of claim 1 , further comprising a nucleotide sequence encoding at least one fiber protein, wherein the nucleotide sequence encoding the at least one fiber protein has at least 90% sequence identity to all or a part of the nucleic acid sequence of any one of SEQ ID NOs: 17, 18, 22-24, 27-29, 32-35, 38, 39, 41, 43-45, 47, 48, 50, 51, and 53.

5. The recombinant adenovirus of claim 1 , further comprising a nucleotide sequence encoding a penton protein, wherein the nucleotide sequence encoding the penton protein has at least 90% sequence identity to all or a part of the nucleic acid sequence of any one of SEQ ID NOs: 107, 110, 111, 113, 114, 116, 117, and 119.

6. A method of treating a subject having a disease, the method comprising administering the recombinant adenovirus of claim 1 to the subject.

7. A method of inducing an immune response in a subject comprising administering the recombinant adenovirus of claim 1 to the subject.

8. The method of claim 7 , wherein the recombinant adenovirus comprises an antigenic gene product or fragment thereof that promotes an immune response in the subject against an infective agent.

9. A method of producing a recombinant adenovirus comprising:

(i) transfecting a cell with an isolated polynucleotide or complement thereof comprising a nucleotide sequence encoding a hexon protein;

(ii) culturing the cell in a suitable medium to allow replication of the polynucleotide in said cell; and

(iii) harvesting recombinant adenovirus from the cell and/or from the medium, wherein the nucleotide sequence encoding the hexon protein has at least 93% sequence identity over the entire sequence of any one of SEQ ID NOs: 55, 58, 59, 61, 62, 64, 65, and 67.

10. The recombinant adenovirus of claim 1 , wherein the nucleotide sequence encoding the hexon protein has at least 95% sequence identity over the entire sequence of any one of SEQ ID NOs: 55, 58, 59, 61, 62, 64, 65, and 67.

11. The recombinant adenovirus of claim 1 , wherein the nucleotide sequence encoding the hexon protein has at least 96% sequence identity over the entire sequence of any one of SEQ ID NOs: 55, 58, 59, 61, 62, 64, 65, and 67.

12. The recombinant adenovirus of claim 1 , wherein the nucleotide sequence encoding the hexon protein has 97% sequence identity over the entire sequence of any one of SEQ ID NOs: 55, 58, 59, 61, 62, 64, 65, and 67.

13. The recombinant adenovirus of claim 1 , wherein the nucleotide sequence encoding the hexon protein has at least 98% sequence identity over the entire sequence of any one of SEQ ID NOs: 55, 58, 59, 61, 62, 64, 65, and 67.

14. The recombinant adenovirus of claim 1 , wherein the nucleotide sequence encoding the hexon protein has at least 99% sequence identity over the entire sequence of any one of SEQ ID NOs: 55, 58, 59, 61, 62, 64, 65, and 67.

15. The recombinant adenovirus of claim 1 , wherein the nucleotide sequence encoding the hexon protein has 100% sequence identity over the entire sequence of any one of SEQ ID NOs: 55, 58, 59, 61, 62, 64, 65, and 67.

16. The method of claim 9 , wherein the nucleotide sequence encoding the hexon protein has at least 94% sequence identity over the entire sequence of any one of SEQ ID NOs: 55, 58, 59, 61, 62, 64, 65, and 67.

17. The method of claim 9 , wherein the nucleotide sequence encoding the hexon protein has at least 96% sequence identity over the entire sequence of any one of SEQ ID NOs: 55, 58, 59, 61, 62, 64, 65, and 67.

18. The method of claim 9 , wherein the nucleotide sequence encoding the hexon protein has at least 95% sequence identity over the entire sequence of any one of SEQ ID NOs: 55, 58, 59, 61, 62, 64, 65, and 67.

19. The method of claim 9 , wherein the nucleotide sequence encoding the hexon protein has at least 97% sequence identity over the entire sequence of any one of SEQ ID NOs: 55, 58, 59, 61, 62, 64, 65, and 67.

20. The method of claim 9 , wherein the nucleotide sequence encoding the hexon protein has 100% sequence identity over the entire sequence of any one of SEQ ID NOs: 55, 58, 59, 61, 62, 64, 65, and 67.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2023
From: BAROUCH, DAN H.; ABBINK, PETER; IAMPIETRO, MARK JUSTIN
To: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
Reel/Frame 065644/0736 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2023
From: HAVENGA, MENZO
To: AVVI BIOTECH INC.
Reel/Frame 065644/0752 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2023
From: AVVI BIOTECH INC.
To: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
Reel/Frame 065644/0769 →
Continuity (5)
Division 16772045
Provisional Application 62641774 · Mar 12, 2018
Provisional Application 62607288 · Dec 18, 2017
Provisional Application 62597268 · Dec 11, 2017
Related Publication 20240287142A1 · Aug 29, 2024
References Cited (123)
US 4695623A · Stabinsky · 1987 [cited by applicant]
US 7247472B2 · Wilson et al. · 2007 [cited by applicant]
US 9718863B2 · Colloca et al. · 2017 [cited by applicant]
US 10106781B2 · Barouch et al. · 2018 [cited by applicant]
US 20040136963A1 · Wilson et al. · 2004 [cited by applicant]
US 20050232900A1 · Vogels et al. · 2005 [cited by applicant]
US 20100034774A1 · Vogels et al. · 2010 [cited by applicant]
US 20110000480A1 · Turner et al. · 2011 [cited by applicant]
US 20110306090A1 · Francky et al. · 2011 [cited by applicant]
US 20120027788A1 · Colloca et al. · 2012 [cited by applicant]
US 20120076812A1 · Barouch et al. · 2012 [cited by applicant]
US 20140348791A1 · Barouch et al. · 2014 [cited by applicant]
US 20150291935A1 · Barouch et al. · 2015 [cited by applicant]
US 20170119872A1 · O'Hagan et al. · 2017 [cited by applicant]
US 20190136205A1 · Barouch et al. · 2019 [cited by applicant]
CN 1578678A · 2005 [cited by applicant]
EP 1944043A1 · 2008 [cited by applicant]
JP 2005523730A · 2005 [cited by applicant]
JP 2020184997A · 2020 [cited by applicant]
WO WO9700326A1 · 1997 [cited by applicant]
WO WO0070071A1 · 2000 [cited by applicant]
WO WO0102607A1 · 2001 [cited by applicant]
WO WO0222080A2 · 2002 [cited by applicant]
WO WO0240665A2 · 2002 [cited by applicant]
WO WO2003046124A2 · 2003 [cited by applicant]
WO WO2004001032A2 · 2003 [cited by applicant]
WO WO2007104792A2 · 2007 [cited by applicant]
WO WO2008010864A2 · 2008 [cited by applicant]
WO WO2011057248A2 · 2011 [cited by applicant]
WO WO2011057254A2 · 2011 [cited by applicant]
WO WO2011129468A1 · 2011 [cited by applicant]
WO WO2012021730A2 · 2012 [cited by applicant]
WO WO2012024351A2 · 2012 [cited by applicant]
WO WO2014078688A2 · 2014 [cited by applicant]
GenBank: MF198449.1 , Rhesus adenovirus 55, complete genome. Dated Dec. 26, 2017. [cited by examiner]
“Sequence alignment results, EMBOSS Needle/Pairwise Sequence Alignment/EMBLE-EBI website,” <https://www.ebi.ac.uk/Tools/psa/emboss_needle/nucleotide.html>, retrieved on Feb. 15, 2019 (10 pages). [cited by applicant]
“UniProt: A0A0M5L3Y8,” UniProt (2015) (2 pages). [cited by applicant]
“UniProtKB: Q5C8P9,” UniProtKB, <https://www.uniprot.org/uniprot/Q5C8P9> (2005) (7 pages). [cited by applicant]
Abbink et al. “Rapid Cloning of Novel Rhesus Adenoviral Vaccine Vectors,” J Virol. 92(6):e01924-17 (2018) (11 pages). [cited by applicant]
Abbink et al., “Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D,” J Virol. 81(9):4654-63 (2007). [cited by applicant]
Abbink et al., “Construction and Evaluation of Novel Rhesus Monkey Adenovirus Vaccine Vectors,” J Virol. 89(3):1512-22 (2015) (11 pages). [cited by applicant]
Abbink et al., “Development of Novel Simian Adenovirus Based Vaccine Vectors.” Poster, 2013. <http://epostersonline.s3.amazonaws.com>. Retrieved on Apr. 16, 2014 (1 page). [cited by applicant]
Awasthi et al., “A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens to Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid a… [cited by applicant]
Bangari et al. “Development of nonhuman adenoviruses as vaccine vectors,” Vaccine 24(7):849-62 (2006) (21 pages). [cited by applicant]
Barouch et al. “Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity,” J Immunol. 172(10):6290-7 (2004) (9 pages). [cited by applicant]
Barouch et al. “International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations,” Vaccine. 29(32):5203-9 (2011) (14 pages). [cited by applicant]
Communication Pursuant to 164(1) EPC for European Patent Application No. 18889863.9, dated Nov. 3, 2021 (22 pages). [cited by applicant]
Communication Pursuant to 94(3) EPC for European Patent Application No. 13854932.4, dated Sep. 28, 2017 (8 pages). [cited by applicant]
Communication pursuant to Article 94(3) EPC for European Application No. 1979450.2, dated May 13, 2020 (5 pages). [cited by applicant]
Communication Pursuant to Rules 70(2) and 70a(2) EPC for International Patent Application No. PCT/US2013/070353, dated Jul. 5, 2016 (1 page). [cited by applicant]
Dicks et al. “A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity,” PLoS One 7(7):e40385 (Jul. 2012) (12 pages). [cited by applicant]
EMBOSS Needle, “Pairwise Sequence Alignment (NUCLEOTIDE),” https://www.ebi.ac.uk/Tools/psa/emboss_needle/nucleotide.html, retrieved Feb. 28, 2019 (10 pages). [cited by applicant]
EMBOSS Needle, “Pairwise Sequence Alignment (PROTEIN),” http://www.ebi.ac.uk/Tools/psa/emboss_needle/, retrieved Aug. 18, 2017 (40 pages). [cited by applicant]
Examination Report for Australian Patent Application No. 2018229561, dated Jun. 21, 2019 (4 pages). [cited by applicant]
Examination Review Report for Singaporean Patent Application No. 11201503864T, dated Apr. 22, 2019 (4 pages). [cited by applicant]
Extended European Search Report for European Patent Application No. 13854932.4, mailed Jun. 17, 2016 (8 pages). [cited by applicant]
Extended European Search Report for European Patent Application No. 18889863.9, dated Mar. 10, 2022 (24 pages). [cited by applicant]
Extended European Search Report for European Patent Application No. 19179450.2, dated Oct. 9, 2019 (7 pages). [cited by applicant]
Finkbeiner, et al., “Metagenomic analysis of human diarrhea: viral detection and discovery,” PLoS Pathog. 4(2):e1000011 (2008) (9 pages). [cited by applicant]
First Examination Report for New Zealand Patent Application No. 708144, dated Mar. 13, 2019 (5 pages). [cited by applicant]
Foy et al. “Probable Non-Vector-borne Transmission of Zika Virus, Colorado, USA,” Emerg Infect Dis. 17(5):880-2 (2011) (7 pages). [cited by applicant]
Geisbert et al. “Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge,” J Virol. 85(9):4222-33 (2011). [cited by applicant]
GenBank Accession No. AF326321.1. Retrieved on Apr. 16, 2014 (3 pages). [cited by applicant]
GenBank Accession No. AY771780. Retrieved Oct. 24, 2017 (17 pages). [cited by applicant]
GenBank Accession No. AY771780.1. Retrieved on Apr. 16, 2014 (15 pages). [cited by applicant]
GenBank Accession No. AZ111781.1. Retrieved on Jul. 13, 2016 (2 pages). [cited by applicant]
GenBank Accession No. AZI11781.1. Retrieved Jan. 7, 2020 (2 Pages). [cited by applicant]
GenBank Accession No. JA453575.1. Retrieved on Jul. 13, 2016 (8 pages). [cited by applicant]
GenBank Accession No. KM591901.1, “Rhesus adenovirus 51, complete genome,” <https://www.ncbi.nlm.nih.gov/nuccore/KM591901.1>, dated Apr. 21, 2015 (11 pages). [cited by applicant]
GenBank Accession No. KM591902.1, “Rhesus adenovirus 52, complete genome,” <https://www.ncbi.nlm.nih.gov/nuccore/KM591902>, dated Apr. 21, 2015 (11 pages). [cited by applicant]
GenBank Accession No. KM591903.1, “Rhesus adenovirus 53, complete genome,” <https://www.ncbi.nlm.nih.gov/nuccore/KM591903>, dated Apr. 21, 2015 (11 pages). [cited by applicant]
GenBank Accession No. KP329562.1, “Simian adenovirus 11 strain P-10, complete genome,” dated Jan. 29, 2016 (18 pages). [cited by applicant]
Handley et al., “Pathogenic simian immunodeficiency virus infection is associated with expansion of the enteric virome,” Cell. 151(2):253-66 (Oct. 2012). [cited by applicant]
Hayes, “Zika virus outside Africa,” Emerg Infect Dis. 15(9):1347-50 (2009). [cited by applicant]
Holterman et al., “Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5,” J Virol. 78(23):13207-15 (2004). [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2018/064978, dated Jun. 16, 2020 (9 pages). [cited by applicant]
International Preliminary Report on Patentability for International Patent Application No. PCT/US2013/070353, dated May 19, 2015 (8 pages). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US02/33645, mailed Sep. 30, 2003 (4 pages). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US13/70353, mailed May 12, 2014 (3 pages). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2007/010347, mailed May 3, 2008 (4 pages). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2010/055991, mailed Jun. 30, 2011 (6 pages). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2011/048006, mailed Apr. 9, 2012 (3 pages). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2018/064978 dated Apr. 24, 2019 (20 pages). [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US13/70353, mailed May 12, 2014 (17 pages). [cited by applicant]
Kass-Eisler et al., “Circumventing the immune response to adenovirus-mediated gene therapy,” Gene Ther. 3(2):154-62 (1996) (10 pages). [cited by applicant]
Kass-Eisler et al., “The Impact of Developmental Stage, Route of Administration and the Immune System on Adenovirus-Mediated Gene Transfer,” Gene Ther. 1(6):395-402 (1994). [cited by applicant]
Kovacs et al., “Complete genome sequence of simian adenovirus 1: an Old World monkey adenovirus with two fiber genes,” Journal of General Virology. 86(6):1681-6 (2005). [cited by applicant]
Kubo, “The Task of Isolating and Identifying Human Pathogenic Viruses,” Seikatsu Eisei. 50(5):381-6 (2006) (English language abstract included). [cited by applicant]
Kuno et al., “Full-length sequencing and genomic characterization of Bagaza, Kedougou, and Zika viruses,” Arch Virol. 152(4):687-96 (2007). [cited by applicant]
Larocca et al., “Vaccine protection against Zika virus from Brazil,” Nature. 536(7617):474-8 (2016) (15 pages). [cited by applicant]
Lemckert et al., “Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity,” J Virol. 79(15):9694-701 (2005). [cited by applicant]
Letvin et al., “Prospects for vaccine protection against HIV-1 infection and AIDS,” Annu Rev Immunol. 20:73-99 (2002). [cited by applicant]
Liu et al., “Modulation of DNA vaccine-elicited CD8+ T-lymphocyte epitope immunodominance hierarchies,” J Virol. 80(24):11991-7 (2006). [cited by applicant]
Morris et al., “Simian adenoviruses as vaccine vectors,” Future Virol. 11(9):649-659 (Sep. 2016). [cited by applicant]
NCBI Nucleotide Database Accession No. KM591901.1. Retrieved on Dec. 14, 2021 (11 pages). [cited by applicant]
NCBI Nucleotide Database Accession No. KM591902.1. Retrieved on Dec. 15, 2021 (11 pages). [cited by applicant]
NCBI Nucleotide Database Accession No. KM591903.1. Retrieved on Dec. 15, 2021 (11 pages). [cited by applicant]
Notice of Reasons for Rejection for Japanese Patent Application No. 2015-542833, mailed Sep. 5, 2017 (20 pages). [cited by applicant]
Office Action for Chinese Patent Application No. 201380068078.0, mailed Apr. 4, 2018 (5 pages). [cited by applicant]
Office Action for Israeli Patent Application No. 238847, dated May 27, 2019 (5 pages). [cited by applicant]
Office Action for Japanese Patent Application No. 2015-542833, mailed Apr. 22, 2020 (4 pages). [cited by applicant]
Office Action for Japanese Patent Application No. 2015-542833, mailed Aug. 7, 2018 (8 pages). [cited by applicant]
Office Action for Japanese Patent Application No. 2018-038380, dated Mar. 10, 2020 (16 pages). [cited by applicant]
Office Action for Japanese Patent Application No. 2018-038380, Mar. 12, 2019 (28 pages). [cited by applicant]
Ostapchuk et al., “Pseudopackaging of adenovirus type 5 genomes into capsids containing the hexon proteins of adenovirus serotypes B, D, or E,” J Virol. 75(1):45-51 (2001). [cited by applicant]
Pantóet al., “Taxonomy Proposal For Old World Monkey Adenoviruses: Characterisation of Several Non-Human, Non-Ape Primate Adenovirus Lineages,” Arch Virol. 160: 3165-77 (2015) (14 pages). [cited by applicant]
Poland et al., “Development of vaccines against Zika virus,” Lancet Infect Dis. 18(7):e211-e219 (Jul. 2018) (9 pages). [cited by applicant]
Search Report for Singaporean Application No. 11201503864T, dated Feb. 29, 2016 (3 pages). [cited by applicant]
Setoguchi et al., “Intraperitoneal In Vivo Gene Therapy to Deliver alpha1-Antitrypsin to the Systemic Circulation,” Am J Respir Cell Mol Biol. 10(4):369-77 (1994). [cited by applicant]
Shiver et al., “Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors,” Annu Rev Med. 55:355-72 (2004). [cited by applicant]
Shiver et al., “Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity,” Nature. 415(6869):331-5 (2002). [cited by applicant]
Sprangers et al., “Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors,” J Clin Microbiol. 41(11):5046-52 (2003). [cited by applicant]
Sumida et al., “Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein,” J Immunol. 174(11):7179-85 (2005). [cited by applicant]
Tripp et al., “Development of a Zika vaccine,” Expert Rev Vaccines. 15(9):1083-5 (2016). [cited by applicant]
Vogels et al., “Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity,” J Virol. 77(15):8263-71 (2003). [cited by applicant]
Wodrich et al., “Switch from capsid protein import to adenovirus assembly by cleavage of nuclear transport signals,” Embo J. 22(23):6245-55 (2003). [cited by applicant]
Written Opinion for Singaporean Application No. 11201503864T, dated Apr. 1, 2016 (6 pages). [cited by applicant]
Wu et al., “Flexibility of the adenovirus fiber is required for efficient receptor interaction,” J Virol. 77(13): 7225-35 (Jul. 2003). [cited by applicant]
Yei et al., “Adenovirus-mediated Gene Transfer for Cystic Fibrosis: Quantitative Evaluation of Repeated in Vivo Vector Administration to the Lung,” Gene Ther. 1(3):192-200 (1994). [cited by applicant]
Zabner et al., “Safety and efficacy of repetitive adenovirus-mediated transfer of CFTR cDNA to airway epithelia of primates and cotton rats,” Nat Genet. 6(1):75-83 (1994). [cited by applicant]
Annonymous., “Rhesus adenovirus 51, complete genome—Nucleotide—NCBI,” (2015) (10 pages). [cited by applicant]
Office Action for Japanese Patent Application No. 2022-057870, Jan. 10, 2023 (3 pages). [cited by applicant]
English Translation of Office Action for Japanese Patent Application No. 2022-057870, mailed Jul. 4, 2023 (8 pages). [cited by applicant]